Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?

被引：8
作者：
Wojtukiewicz, Marek Z. [1 ,2 ]
Pogorzelska, Magda [2 ]
Politynska, Barbara [3 ]
机构：
[1] Med Univ Bialystok, Dept Oncol, Bialystok, Poland
[2] Comprehens Canc Ctr, Dept Clin Oncol, Bialystok, Poland
[3] Med Univ Bialystok, Dept Psychol & Philosophy, Bialystok, Poland
来源：
CANCER AND METASTASIS REVIEWS | 2022年 / 41卷 / 03期
关键词：
Triple negative; Breast cancer; TNBC; Immunotherapy; Future targets;
D O I：
10.1007/s10555-022-10060-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：465 / 469
页数：5
相关论文
共 16 条
[1]   Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies [J].
Ashraf, Yahya ;
Mansouri, Hanane ;
Laurent-Matha, Valerie ;
Alcaraz, Lindsay B. ;
Roger, Pascal ;
Guiu, Severine ;
Derocq, Danielle ;
Robin, Gautier ;
Michaud, Henri-Alexandre ;
Delpech, Helene ;
Jarlier, Marta ;
Pugniere, Martine ;
Robert, Bruno ;
Puel, Anthony ;
Martin, Lucie ;
Landomiel, Flavie ;
Bourquard, Thomas ;
Achour, Oussama ;
Fruitier-Arnaudin, Ingrid ;
Pichard, Alexandre ;
Deshayes, Emmanuel ;
Turtoi, Andrei ;
Poupon, Anne ;
Simony-Lafontaine, Joelle ;
Boissiere-Michot, Florence ;
Pirot, Nelly ;
Bernex, Florence ;
Jacot, William ;
du Manoir, Stanislas ;
Theillet, Charles ;
Pouget, Jean-Pierre ;
Navarro-Teulon, Isabelle ;
Bonnefoy, Nathalie ;
Pelegrin, Andre ;
Chardes, Thierry ;
Martineau, Pierre ;
Liaudet-Coopman, Emmanuelle .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[2]   Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment [J].
Chen, Wuzhen ;
Shen, Lesang ;
Jiang, Jingxin ;
Zhang, Leyi ;
Zhang, Zhigang ;
Pan, Jun ;
Ni, Chao ;
Chen, Zhigang .
BIOMARKER RESEARCH, 2021, 9 (01)
[3]   Immunotherapy in Triple-Negative Breast Cancer [J].
Emens, Leisha A. .
CANCER JOURNAL, 2021, 27 (01) :59-66
[4]   Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC [J].
Herbst, Roy S. ;
Giaccone, Giuseppe ;
de Marinis, Filippo ;
Reinmuth, Niels ;
Vergnenegre, Alain ;
Barrios, Carlos H. ;
Morise, Masahiro ;
Felip, Enriqueta ;
Andric, Zoran ;
Geater, Sarayut ;
Ozguroglu, Mustafa ;
Zou, Wei ;
Sandler, Alan ;
Enquist, Ida ;
Komatsubara, Kimberly ;
Deng, Yu ;
Kuriki, Hiroshi ;
Wen, Xiaohui ;
McCleland, Mark ;
Mocci, Simonetta ;
Jassem, Jacek ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) :1328-1339
[5]   Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment [J].
Lan, Jie ;
Lu, Haiquan ;
Samanta, Debangshu ;
Salman, Shaima ;
Lu, You ;
Semenza, Gregg L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (41) :E9640-E9648
[6]   Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy [J].
Lee, Dong-Hee ;
Choi, Seunghyun ;
Park, Yoon ;
Jin, Hyung-seung .
PHARMACEUTICALS, 2021, 14 (10)
[7]   Leveraging epigenetics to enhance the efficacy of immunotherapy [J].
Licht, Jonathan D. ;
Bennett, Richard L. .
CLINICAL EPIGENETICS, 2021, 13 (01)
[8]   Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer [J].
Luo, Chenyi ;
Wang, Peipei ;
He, Siqi ;
Zhu, Jingjing ;
Shi, Yuanyuan ;
Wang, Jianxun .
FRONTIERS IN ONCOLOGY, 2022, 12
[9]   Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells [J].
Ly, Stanley ;
Anand, Vivek ;
El-Dana, Fouad ;
Nguyen, Khoa ;
Cai, Yiming ;
Cai, Shirong ;
Piwnica-Worms, Helen ;
Tripathy, Debasish ;
Sahin, Aysegul A. ;
Andreeff, Michael ;
Battula, Venkata Lokesh .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
[10]   Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer [J].
Miles, D. ;
Gligorov, J. ;
Andre, F. ;
Cameron, D. ;
Schneeweiss, A. ;
Barrios, C. ;
Xu, B. ;
Wardley, A. ;
Kaen, D. ;
Andrade, L. ;
Semiglazov, V ;
Reinisch, M. ;
Patel, S. ;
Patre, M. ;
Morales, L. ;
Patel, S. L. ;
Kaul, M. ;
Barata, T. ;
O'Shaughnessy, J. .
ANNALS OF ONCOLOGY, 2021, 32 (08) :994-1004
12